Aytu BioScience's Sublicensee SUDA Pharmaceuticals Secures TGA Approval, Enabling Near-Term Commercialization of ZolpiMist
ENGLEWOOD, CO / ACCESSWIRE / July 30, 2020 / Aytu BioScience , Inc. (NASDAQ:AYTU), a specialty pharmaceutical company (the "Company") focused on commercializing novel products that address significant patient needs, today announced the approval of ZolpiMist (zolpidem tartrate oral spray) by the Therapeutic Goods Administration (TGA) in Australia. This approval, which was secured by the Company's ZolpiMist sublicensee SUDA Pharmaceuticals Ltd ("SUDA"), enables near-term commercialization of ZolpiMist in Australia. SUDA (ASX:SUD) is a publicly-listed drug delivery company focused on oro-mucosal administration and is headquartered in Perth, Western Australia.
With this approval by Australia's TGA, ZolpiMist will be included on the Australian Register of Therapeutic Goods and can now be commercialized and supplied within Australia. Further, this approval will assist SUDA's current ZolpiMist sublicensees, Teva Pharmaceuticals, Mitsubishi Tanabe Pharma Singapore and MTP Korea, in their submissions in their respective territories.
On March 9, 2010 Aytu BioScience announced a global distribution agreement for ZolpiMist with SUDA whereby the Company assumed a milestone and royalty-based licensing agreement with SUDA. As specified in the companies' global licensing agreement, SUDA will pay Aytu a portion of each upfront and milestone payment received from sublicensees, and Aytu will receive ongoing royalty payments on sales generated by SUDA's sublicensees as ZolpiMist is launched in each territory.
Josh Disbrow, Chief Executive Officer of Aytu BioScience, stated, "We congratulate the SUDA team for obtaining TGA approval for ZolpiMist and look forward to SUDA and their partners moving ZolpiMist closer to commercialization in Australia and elsewhere. This is an exciting time for SUDA and represents an important milestone for Aytu as we move closer to realizing ex-US licensing revenue for ZolpiMist."
Dr. Michael Baker, Chief Executive Officer and Managing Director of SUDA, commented, "The TGA submission was a combined effort by SUDA's technical team as well as our regulatory consultant, Pharma To Market. Obtaining the approval indicates the calibre of our staff and is also a key benefit to our partners for ZolpiMist. We are delighted by the outcome and look forward to seeing the commencement of commercial sales in the foreseeable future."
The global sleep aid market is currently estimated at almost $50 billion in annual revenue, and annual revenue is estimated to reach nearly $80 billion in 2022.
About Aytu BioScience, Inc.Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. The company currently markets a portfolio of prescription products addressing large primary care and pediatric markets. The primary care portfolio includes (i) Natesto, the only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or "Low T"), (ii) ZolpiMist, the only FDA-approved oral spray prescription sleep aid, and (iii) Tuzistra XR, the only FDA-approved 12-hour codeine-based antitussive syrup. The pediatric portfolio includes (i) AcipHex Sprinkle, a granule formulation of rabeprazole sodium, a commonly prescribed proton pump inhibitor; (ii) Cefaclor, a second-generation cephalosporin antibiotic suspension; (iii) Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions; and (iv) Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various for infants and children with fluoride deficiency. Aytu also distributes a COVID-19 IgG/IgM rapid test. This coronavirus test is a solid phase immunochromatographic assay used in the rapid, qualitative and differential detection of IgG and IgM antibodies to the 2019 Novel Coronavirus in human whole blood, serum or plasma.
Aytu also operates a subsidiary focused on consumer health, Innovus Pharmaceuticals, Inc. ("Innovus"), a specialty pharmaceutical company commercializing, licensing and developing safe and effective consumer healthcare products designed to improve men's and women's health and vitality. Innovus commercializes over thirty-five consumer health products competing in large healthcare categories including diabetes, men's health, sexual wellness and respiratory health. The Innovus product portfolio is commercialized through direct-to-consumer marketing channels utilizing the company's proprietary Beyond Human marketing and sales platform.
Aytu's strategy is to continue building its portfolio of revenue-generating Rx and consumer health products, leveraging its focused commercial team and expertise to build leading brands within large therapeutic markets. For more information visit aytubio.com and visit innovuspharma.com to learn about the company's consumer healthcare products.
About SUDA Pharmaceuticals Ltd SUDA Pharmaceuticals Ltd (ASX:SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e.: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist is marketed in the USA and SUDA has rights to the product outside of the US and Canada. Other products in development include oral sprays for the treatment of: migraine headache; chemotherapy-induced nausea and vomiting; erectile dysfunction; pulmonary hypertension; epileptic seizures and pre-procedural anxiety and cancer. For more information, visit http://www.sudapharma.com
Forward-Looking StatementThis press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. All statements other than statements of historical facts contained in this presentation, are forward-looking statements. Forward-looking statements are generally written in the future tense and/or are preceded by words such as ''may,'' ''will,'' ''should,'' ''forecast,'' ''could,'' ''expect,'' ''suggest,'' ''believe,'' ''estimate,'' ''continue,'' ''anticipate,'' ''intend,'' ''plan,'' or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: market and other conditions, the regulatory and commercial risks associated with introducing the COVID-19 rapid test, the effectiveness of the COVID-19 rapid rest, market acceptance of the National Cancer Institute or other independently conducted studies' testing results, the regulatory, clinical, and commercial risks associated with the investigational Healight device, effects of the business combination of Aytu and the Commercial Portfolio and the merger ("Merger") with Innovus Pharmaceuticals, including the combined company's future financial condition, results of operations, strategy and plans, the ability of the combined company to realize anticipated synergies in the timeframe expected or at all, changes in capital markets and the ability of the combined company to finance operations in the manner expected, the diversion of management time on Merger-related issues and integration of the Commercial Portfolio, the ultimate timing, outcome and results of integrating the operations the Commercial Portfolio and Innovus with Aytu's existing operations, risks relating to gaining market acceptance of our products, including the risks associated with ZolpiMist's commercial success in Australia and elsewhere, obtaining or maintaining reimbursement by third-party payors for our prescription products, the potential future commercialization of our product candidates, the anticipated start dates, durations and completion dates, as well as the potential future results, of our ongoing and future clinical trials, the anticipated designs of our future clinical trials, anticipated future regulatory submissions and events, our anticipated future cash position and future events under our current and potential future collaboration. We also refer you to the risks described in ''Risk Factors'' in Part I, Item 1A of the company's Annual Report on Form 10-K and in the other reports and documents we file with the Securities and Exchange Commission from time to time.
Contact for Investors:James CarbonaraHayden IR(646) 755-7412james@haydenir.com
SOURCE: Aytu BioScience, Inc.
View source version on accesswire.com:https://www.accesswire.com/599574/Aytu-BioScience-Announces-Regulatory-Approval-of-ZolpiMistR-by-Australian-Therapeutic-Goods-Administration
- Low T Therapy Market Size, Trends, Production, Demand and Profit Is Statistical Analyzed in 2021 Report: AbbVie, Endo International, Eli Lilly ... - January 24th, 2021
- Healthy Men: What women need to know about men's health - Greater Milwaukee Today - November 20th, 2020
- 24 Ways to Increase Penis Sensitivity: Tips, Techniques, and More - Healthline - October 18th, 2020
- Centrapeak Testosterone Booster Review: Is it Better than Others on the Market? - generationiron.com - October 18th, 2020
- Erectile Dysfunction: A Look at the Most Common Causes - Feed Leader - October 10th, 2020
- Aytu BioScience Announces Fiscal Q4 2020 Net Revenue of $14.9 Million, an Increase of 82% Sequentially, and 766% Year-Over-Year - BioSpace - October 6th, 2020
- Aytu BioScience to Report Fourth Quarter and Full Year Fiscal 2020 Results and Provide Business Update on Tuesday, October 6, 2020 - Yahoo Finance - October 6th, 2020
- Whats Causing My Low Testosterone? - September 29th, 2020
- Indianapolis Low T Center & Men's Clinic | Sleep Apnea ... - September 29th, 2020
- Could This Device Help Save Covid-19 Patients Before the ICU? - Houstonia Magazine - September 6th, 2020
- Aytu BioScience Announces Manufacture and Delivery of Healight(TM) Devices for Use in COVID-19 Clinical Study - Yahoo Finance - August 17th, 2020
- How can you actively boost your low libido? - Big Think - August 11th, 2020
- New Osteoporosis Recommendations From AACE Help Therapy Selection - Medscape - July 25th, 2020
- Hormone therapy no cure-all for 'low T' in ageing men - Health24 - July 20th, 2020
- Strain engineering of the magnetic multipole moments and anomalous Hall effect in pyrochlore iridate thin films - Science Advances - July 20th, 2020
- Does Low Testosterone Cause Night Sweats? - July 7th, 2020
- Treating low testosterone levels - Harvard Health - July 7th, 2020
- Some people who experienced no coronavirus symptoms may now be immune to Covid-19 - here's what the study says - Derry Journal - July 4th, 2020
- AGING: Hormone therapy no cure-all for low T in men - Palm Beach Post - July 2nd, 2020
- COVID 19 Effect on Low T Therapy Market: an Increase in Technology Development Will Heighten Growth of Key Players: AbbVie, Endo International, Eli... - June 23rd, 2020
- Freddy McConnell Gave Birth to His Son. Then His Life Changed. - Esquire - June 18th, 2020
- Low T Therapy Market: What Will Happen to Key Players After COVID 19 Ends: AbbVie, Endo International, Eli Lilly - Cole of Duty - June 9th, 2020
- Ego might drive men to testosterone therapy, but it helps with certain conditions - The Columbus Dispatch - June 8th, 2020
- What Are T-Cells and Can They Protect You from COVID-19? - Labmate Online - June 8th, 2020
- Aytu BioScience to Report Fiscal Q3 FY 2020 Results and Business Update - Yahoo Finance - May 7th, 2020
- COVID-19: T cells offer clues to the potential power of Roche's Actemra - FierceBiotech - May 6th, 2020
- Peek on Low T Therapy Market Future, Extensive Studies and Prediction of Top Manufacturers Condition: AbbVie, Endo International, Eli Lilly - 3rd... - May 6th, 2020
- New clues on how to treat COVID-19 from T cell counts - The Nation - May 3rd, 2020
- Aytu BioScience Signs Development Agreement with Sterling Medical Devices to Advance the Development of Healight as a Potential Coronavirus Treatment... - April 29th, 2020
- Low T Center Is Committed To Meeting The Needs Of Colorado Patients During The COVID-19 Emergency - P&T Community - April 20th, 2020
- Aytu BioScience Announces Positive Results from an Independently Conducted Clinical Study of the Company's Licensed COVID-19 IgG/IgM Point-of-Care... - April 17th, 2020
- The testosterone myth - The Week Magazine - April 12th, 2020
- Low T Therapy Market Industry Analysis, Size, Share, Growth, Trends And Forecast 2020 2024 - Monroe Scoop - March 26th, 2020
- Aytu BioScience Submits Notice of Commercialization to the FDA, Allowing for Company's Distribution of its 2-10 Minute COVID-19 IgG/IgM Point-of-Care... - March 23rd, 2020
- No, not everything about mens sexual behaviour can be explained by testosterone - Scroll.in - March 23rd, 2020
- Letters to the editor - Boston Herald - March 9th, 2020
- Low Testosterone - Symptoms & Treatment | Everyday Health - March 6th, 2020
- Lost revenue from low T fares must be recouped - Boston Herald - March 1st, 2020
- Indiana Regenerative Medicine Institute Offers Innovative Approaches in Regenerative Medicine, Hormone Replacement and Pain Management - Carmel... - March 1st, 2020
- Low Testosterone Causes | Everyday Health - February 24th, 2020
- Diagnosis, treatment and how to avoid osteoporosis - The Gazette - January 30th, 2020
- The Signs a Testosterone Booster is Needed - Science Times - January 22nd, 2020
- New Guideline for Testosterone Treatment in Men With 'Low T' - Medscape - January 9th, 2020
- John R. Hampton III, MD, is recognized by Continental Who's Who - PRNewswire - November 27th, 2019
- Expert Insights on Osteoporosis From the ACR/ARP 2019 Annual Meeting - Rheumatology Advisor - November 27th, 2019
- Low T Specialist - Dallas, TX & Frisco, TX: Men's T-Clinic ... - October 5th, 2019
- Does Insurance Cover Low T Treatment - Mantality Health - October 5th, 2019
- Low Testosterone Therapy (TRT) and Treatment from Low T Center - September 27th, 2019
- Low T Center, 549 East County Line Road, Building 4 Suite D ... - March 31st, 2019
- Low T Symptoms | Low Testosterone | Signs of Low T - March 12th, 2019
- Low T Treatment in Texas & Illinois | SynergenX Health ... - February 18th, 2019
- The Lowdown on Low-T - Discover Health - Rush University ... - February 18th, 2019
- The Low T Scam? - Testosterone Centers of Texas - Low T ... - February 18th, 2019
- Low T 99 - Testosterone Therapy: Bellevue, Seattle, Tacoma ... - December 31st, 2018
- Men, Low T, and the Facts | Lifespan - October 1st, 2018
- Denver Low T Medical Clinic and Testosterone Therapy Center - August 6th, 2018
- You've Heard About "Low T" But What About "Low E"? - April 23rd, 2018
- Low T 99 - 10 Photos - Health & Medical - 1239 120th Ave NE ... - April 23rd, 2018
- Low Testosterone Treatment - Carolina Men's Clinic - April 23rd, 2018
- Low T-Helper (CD4) Cell Level - Symptoms and Diagnosis - March 2nd, 2018
- ED Clinic Nashville TN, Erectile Dysfunction Treatment, Low T - February 10th, 2018
- Low-Testosterone (Low-T) - Controversy Over ... - AARP - January 11th, 2018
- Low testosterone symptoms | Effects of low testosterone - January 11th, 2018
- About Low Testosterone | Low T Center - December 29th, 2017
- Low Testosterone Replacement Therapy | Low T ... - Men's T Clinic - November 12th, 2017
- low t | eBay - November 12th, 2017
- Low Testosterone (Low T) Treatments - onhealth.com - November 2nd, 2017
- Low-T (Low Testosterone) Quiz: Symptoms, Signs & Treatment - October 22nd, 2017
- Erectile Dysfunction/Low T Men's Health Georgia - September 4th, 2017
- 10 easy ways to transform old band T-shirts into something new - Alternative Press - August 30th, 2017
- AbbVie Hit With $150 Million Loss in Low-T Cardiac Trial - Lexology (registration) - August 19th, 2017
- Low T Center returning to sponsor Sorenson - ESPN - August 18th, 2017
- Older men with 'low T' can improve their sex lives with testosterone therapy, study says - Men's Fitness - August 18th, 2017
- Center for Men | Tulsa Men's Clinic | Tulsa Low T - August 17th, 2017
- `Make Men Great Again' Speakers Bash Trans People While Pumping Up America's Girly Men - Southern Poverty Law Center - August 10th, 2017
- Doctors Address Low Testosterone Ads - CBS St. Louis - August 9th, 2017
- Low T - Testosterone Replacement Therapy - Ehormones - August 2nd, 2017
- What does a low T cell count mean? DoctorNDTV Queries - August 2nd, 2017
- Column: Testosterone treatment reserved for men with symptoms ... - The Daily Courier - July 5th, 2017
- Testosterone treatment reserved for men with symptoms - Sarasota Herald-Tribune - July 5th, 2017